M&A / Healthcare
Merck KGaA to Buy Silence Therapeutics for $1.3 Billion at a 130% Premium
The German drugmaker will pay $20 in cash for each Silence ADS — more than double Friday's close — for a London gene-silencing pipeline led by divesiran, in a U.K. scheme expected to close in early 2027.